Subscribe
Evofem Biosciences and the first ever non-hormonal contraception – Episode 61

FemTech Focus

Evofem Biosciences and the first ever non-hormonal contraception – Episode 61

Saundra Pelletier is the CEO of Evofem Biosciences, a biopharmaceutical company developing innovative women's sexual and reproductive health products.  In September 2020, Saundra led the successful launch of Phexxi –…
November 9, 2020
ADVERTISEMENT
EHRGo-THE FUTURE OF HEALTHCARE EDUCATION

Evofem Biosciences and the first ever non-hormonal contraception – Episode 61

Saundra Pelletier is the CEO of Evofem Biosciences, a biopharmaceutical company developing innovative women’s sexual and reproductive health products.  In September 2020, Saundra led the successful launch of Phexxi – the first and only FDA-approved non-hormonal, female-controlled, on-demand prescription contraceptive vaginal gel.  Saundra is also advancing the Company’s pipeline product, EVO100, into a Phase 3 clinical trial for prevention of urogenital chlamydia and gonorrhea in women.  During her tenure, Saundra has led multiple equity financing rounds, raising more than $425 million in capital.  Prior to joining Evofem, Saundra founded WCG, a global non-profit organization focused on creating access to reproductive health products in over 100 developing countries.  Saundra is a breast cancer survivor, single mother, published author, skilled moderator, and coveted keynote speaker.  She was recently named to Inc. Magazine’s 2020 Female Founders 100 List. We discussed Phexxi’s launch and becoming a public company.

Check out Evofem at evofem.com and Phexxi at phexxi.com
Rate, Review & Subscribe!

ADVERTISEMENT
EHRGo-THE FUTURE OF HEALTHCARE EDUCATION

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

Top Health Podcasts. Delivered to Your Inbox and Eardrums.

Proudly supported by:

cover
Medicines360 is constructing healthcare for women everywhere Dr. Jessica Grossman is the CEO of Medicines360, discusses increasing affordability and accessibility in women's health, equity in clinical studies, and demystifying birth control.